^
BIOMARKER:

MET amplification

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET amplification
NSCLC
c-MET inhibitor
Sensitive: C3 – Early Trials
Exp Hematol Oncol - 4 weeks
MET amplification
NSCLC
crizotinib
Sensitive: A2 - Guideline
MET amplification
RCC
savolitinib
Sensitive: A2 - Guideline
MET amplification
Gastroesophageal Junction Adenocarcinoma
AMG 102
Resistant: B - Late Trials
MET amplification
Gastric Adenocarcinoma
AMG 102
Resistant: B - Late Trials
MET amplification
NSCLC
crizotinib + bevacizumab
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
SCC244
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
gefitinib + CT053PTSA
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
erlotinib
Resistant: C2 – Inclusion Criteria
MET amplification
NSCLC
osimertinib + savolitinib
Sensitive: C2 – Inclusion Criteria
MET amplification
Lung Cancer
tepotinib
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
APL-101
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
crizotinib + osimertinib
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
capmatinib
Sensitive: C2 – Inclusion Criteria
MET amplification
Gastric Cancer
savolitinib
Sensitive: C2 – Inclusion Criteria
MET amplification
RCC
crizotinib
Sensitive: C2 – Inclusion Criteria
MET amplification
Head and Neck Cancer
crizotinib
Sensitive: C2 – Inclusion Criteria
MET amplification
NSCLC
tepotinib
Sensitive: C2 – Inclusion Criteria
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive: C3 – Early Trials
MET amplification
NSCLC
U3-1402
Sensitive: C3 – Early Trials
MET amplification
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
MET amplification
Gallbladder Cancer
crizotinib
Sensitive: C3 – Early Trials
MET amplification
CRC
TPX-0022
Sensitive: C3 – Early Trials
MET amplification
Gastric Cancer
TPX-0022
Sensitive: C3 – Early Trials
MET amplification
NSCLC
gefitinib + savolitinib
Sensitive: C3 – Early Trials
MET amplification
Solid Tumor
TQ-B3101
Sensitive: C3 – Early Trials
MET amplification
Gastric Cancer
crizotinib
Sensitive: C3 – Early Trials
MET amplification
LUAD
crizotinib + osimertinib
Sensitive: C3 – Early Trials
MET amplification
NSCLC
gefitinib
Resistant: C3 – Early Trials
MET amplification
GastroEsophageal Cancer
crizotinib
Sensitive: C3 – Early Trials
MET amplification
LUAD
crizotinib
Sensitive: C3 – Early Trials
MET amplification
CRC
cetuximab
Resistant: C3 – Early Trials
MET amplification
CRC
panitumumab
Resistant: C3 – Early Trials
MET amplification
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
MET amplification
LUAD
erlotinib + gefitinib + icotinib
Sensitive: C3 – Early Trials
MET amplification
GastroEsophageal Cancer
afatinib
Resistant: C3 – Early Trials
MET amplification
NSCLC
osimertinib
Resistant: C3 – Early Trials
MET amplification
NSCLC
lorlatinib
Resistant: C3 – Early Trials
MET amplification
Sarcoma
crizotinib
Sensitive: C3 – Early Trials
MET amplification
NSCLC
gefitinib + tepotinib
Sensitive: C3 – Early Trials
MET amplification
Pancreatic Cancer
cetuximab
Resistant: C4 – Case Studies
MET amplification
Biliary Tract Cancer
crizotinib
Sensitive: C4 – Case Studies
MET amplification
Cholangiocarcinoma
c-MET inhibitor
Sensitive: C4 – Case Studies
MET amplification
GBM
crizotinib
Sensitive: C4 – Case Studies
MET amplification
GBM
cediranib
Resistant: C4 – Case Studies
MET amplification
Gastric Adenocarcinoma
RG3638
Sensitive: C4 – Case Studies
MET amplification
NSCLC
selpercatinib
Resistant: C4 – Case Studies
MET amplification
HCC
crizotinib
Sensitive: C4 – Case Studies
MET amplification
NSCLC
osimertinib + HQP8361
Sensitive: D – Preclinical
MET amplification
NSCLC
HQP8361
Sensitive: D – Preclinical
MET amplification
NSCLC
CKD-702
Sensitive: D – Preclinical
MET amplification
NSCLC
afatinib
Resistant: D – Preclinical
MET amplification
Gastric Cancer
JNJ-38877605
Sensitive: D – Preclinical
MET amplification
Gastric Cancer
SGX523
Sensitive: D – Preclinical